



PATENT
Docket No. 00403.CN1
(M&R 268.04030121/Pfizer 026885)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Benson et al.)	Group Art Unit:	1652
)		
Serial No.: 10/028,224)	Examiner:	David J. Steadman
Confirmation No.: 4497)		
)		
Filed: December 21, 2001)		
)		
For:			
CRYSTALLIZATION AND STRUCTURE DETERMINATION OF GLYCOSYLATED HUMAN BETA SECRETASE, AN ENZYME IMPLICATED IN ALZHEIMER'S DISEASE			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Supplemental Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

Supplemental Information Disclosure Statement

Page 2 of 2

Applicant(s): Benson et al.

Serial No.: 10/028,224

Confirmation No.: 4497


Filed: December 21, 2001

For: CRYSTALLIZATION AND STRUCTURE DETERMINATION OF GLYCOSYLATED HUMAN BETA
SECRETASE, AN ENZYME IMPLICATED IN ALZHEIMER'S DISEASE

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Name: Kelly J. McNulty
"Express Mail" mailing label number:
EV 201890564 US
Date of Deposit: February 15, 2005


February 15, 2005
Date

Respectfully submitted for

Benson et al.

By
Muetting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
Customer Number 26813

By: 
Loren D. Albin
Reg. No. 37,763
Direct Dial (612)305-1225

INFORMATION DISCLOSURE STATEMENT 	Atty. Docket No.: 00403.CN1	Serial No.: 10/028,224
	Applicant(s): Benson et al.	Confirmation No.: 4497
	Application Filing Date: December 21, 2001	Group: 1652
	Information Disclosure Statement mailed: February 15, 2005	

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		None					


FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	X	WO 03/012089 A3	02/13/03	PCT				

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	Alvares et al., "Rat urate oxidase produced by recombinant baculovirus expression: Formation of peroxisome crystalloid core-like structures," <i>Proc. Natl Acad. Sci. USA</i> , June 1992;89:4908-4912.
	X	Dealwis et al., "X-ray Analysis at 2.0 Å Resolution of Mouse Submaxillary Renin Complexed with a Decapeptide Inhibitor CH-66, Based on the 4-16 Fragment of Rat Angiotensinogen," <i>J Mol Biol</i> , 1994;236:342-360.
	X	Giegé et al., "Crystallogenes of Biological Macromolecules: Facts and Perspectives," <i>Acta Cryst.</i> , 1994;D50:339-350.
	X	Kervinen et al., "Toward a universal inhibitor of retroviral proteases: Comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIIV," <i>Protein Science</i> , November 1998;7:2314-2323.
	X	McPherson et al., "The Science of Macromolecular crystallization," <i>Structure</i> , 15 August 1995;3:759-768.
	X	Tang et al., "Structural evidence for gene duplication in the evolution of the acid proteases," <i>Nature</i> , 16 February 1978;271:618-621.

EXAMINER	Date Considered
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT 	Atty. Docket No.: 00403.CN1	Serial No.: 10/028,224
	Applicant(s): Benson et al.	Confirmation No.: 4497
	Application Filing Date: December 21, 2001	Group: 1652
	Information Disclosure Statement mailed: February 15, 2005	

Examiner Initial	Enclosed	Document Description
	X	Van Der Klei et al., "Biosynthesis and Assembly of Alcohol Oxidase, A Peroxisomal Matrix Protein in Methylophilic Yeasts: A Review," <i>Yeast</i> , 1991;7:195-209.
	X	Wang et al., "Crystallization of glycosylated human BACE protease domain expressed in <i>Trichoplusia ni</i> ," <i>Biochimica et Biophysica Acta</i> , 2004;1698:255-259. (Available online 21 January 2004).
	X	Witkowski et al., "Conversion of a β -Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine," <i>Biochemistry</i> , 1998;38:11643-11650. (Published on Web August 18, 1999).

EXAMINER	Date Considered
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	